An Expanded Access Protocol for ZMapp (Anti-Ebola monoclonal antibody)
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Porgaviximab (Primary)
- Indications Ebola virus infections
- Focus Therapeutic Use
- 27 Oct 2016 New trial record
- 12 Oct 2016 According to a Mapp Biopharmaceutical media release, the U.S. Food and Drug Administration (FDA) has approved an Expanded Access Protocol (EAP) for ZMapp. The company will also make appropriate regulatory submissions in the three West African countries that participated in PREVAIL II, and will make ZMapp available to Ebola patients wishing to have access to this experimental treatment in participating countries.